Pronethalol hydrochloride is a non-selective β-adrenergic antagonist; it acts as a potent inhibitor of Sox2 expression; it prevents and reverses digitalis-induced ventricular arrhythmias; it ameliorates cerebral arteriovenous malformations (AVMs); it represses EGFP expression in a dose- and time-dependent manner in ReNcell VM cells; it reduces Sox2 expression to less than 10% after 2 days of treatment; it stabilizes endothelial differentiation and lumen formation in Mgp–/– mice.